{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["73(7)"],"submitter":["Zhang P"],"pubmed_abstract":["<h4>Background</h4>The programmed death 1 inhibitor toripalimab plus the angio-immuno kinase inhibitor surufatinib showed a tolerable safety profile and preliminary efficacy in patients with advanced solid tumors in a phase I study.<h4>Methods</h4>This open-label, multi-cohort study in China enrolled patients with advanced solid tumors who had failed or were intolerable to standard treatment into tumor-specific cohorts. Patients received surufatinib (250 mg orally, once daily) plus toripalimab (240 mg intravenously, once every three weeks). Results for three cohorts (gastric/gastroesophageal junction [GC/GEJ] adenocarcinoma, esophageal squamous cell carcinoma [ESCC], and biliary tract carcinoma [BTC]) are reported here. The primary endpoint was investigator-assessed objective response rate"],"journal":["Cancer immunology, immunotherapy : CII"],"pagination":["119"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11076424"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer."],"pmcid":["PMC11076424"],"pubmed_authors":["Shen L","Shi M","Shi S","Zhong C","Xu J","Cheng Y","Fan S","Zhang P","Song L","Lu M","Li Z","Yin F","Chen Z","Zhang Y","Zhang X","Ye F","Tan P","Su W"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.","description":"<h4>Background</h4>The programmed death 1 inhibitor toripalimab plus the angio-immuno kinase inhibitor surufatinib showed a tolerable safety profile and preliminary efficacy in patients with advanced solid tumors in a phase I study.<h4>Methods</h4>This open-label, multi-cohort study in China enrolled patients with advanced solid tumors who had failed or were intolerable to standard treatment into tumor-specific cohorts. Patients received surufatinib (250 mg orally, once daily) plus toripalimab (240 mg intravenously, once every three weeks). Results for three cohorts (gastric/gastroesophageal junction [GC/GEJ] adenocarcinoma, esophageal squamous cell carcinoma [ESCC], and biliary tract carcinoma [BTC]) are reported here. The primary endpoint was investigator-assessed objective response rate","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-06-01T11:55:58.346Z","creation":"2026-04-08T12:01:56.536Z"},"accession":"S-EPMC11076424","cross_references":{"pubmed":["38713205"],"doi":["10.1007/s00262-024-03677-7"]}}